Quantcast
Last updated on April 16, 2014 at 13:39 EDT

Latest Duchenne muscular dystrophy Stories

2012-02-21 11:00:00

Grant Funds Work of Tivorsan Pharmaceuticals' Team to Bring Recombinant Biglycan to the Clinic for the Possible Treatment of Duchenne Muscular Dystrophy HACKENSACK, N.J., Feb. 21, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it will award Tivorsan Pharmaceuticals (Tivorsan) a $500,000 grant to develop the company's biglycan therapeutic candidate for Duchenne muscular dystrophy. (Logo:...

2012-02-09 23:42:19

Twelve weeks of training geared towards improving muscular power in older people are highly effective for improving their functional capacity and quality of life, as shown by the studies carried out by the “Biomechanics and Physiology of Movement” research group at the Public University of Navarre led by Professor Mikel Izquierdo-Redin. The results of these pieces of research, conducted in collaboration with the University of Trás-os-Montes e Alto Douro (Portugal)...

2012-02-01 15:05:00

TUCSON, Ariz., Feb. 1, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association's latest round of grants allocates more than $12 million to the support of 38 research projects investigating the causes of, and potential treatments for, a number of forms of neuromuscular disease. "MDA is strongly committed to funding important and exciting basic research that will serve as the basis of future therapies for neuromuscular disease," said MDA Chairman of the Board R. Rodney Howell, M.D....

2012-02-01 10:00:00

Leading Duchenne Muscular Dystrophy Organization to Receive Donation from The Caring Valley(TM) HACKENSACK, N.J., Feb. 1, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it has been selected as a featured charity in The Caring Valley, an area on the Webkinz World(TM) site that teaches children about child-focused nonprofits in a fun environment. PPMD Founding President and CEO was thrilled that Duchenne is receiving this kind of national...

2012-01-05 02:00:00

TUCSON, Ariz. and PROVIDENCE, R.I., Jan. 5, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association (MDA) today announced it has awarded $1.0 million to Tivorsan Pharmaceuticals to help speed pre-clinical work vital to a filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a recombinant humanized form of biglycan as a potential muscular dystrophy treatment. The new funding to the Providence-based biotechnology firm comes from...

2012-01-04 07:00:00

NEWTON, Mass., Jan. 4, 2012 /PRNewswire/ -- Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, today announced that the United States Food and Drug Administration (FDA) granted orphan drug designation for HT-100 for treatment of Duchenne muscular dystrophy (DMD). DMD is a progressive and fatal neuromuscular disorder, which afflicts approximately 1 in 3,500 boys worldwide. HT-100, also known as halofuginone, is an orally...

2012-01-02 23:07:44

Researchers describe how increased production of a microRNA promotes progressive muscle deterioration in a mouse model of Duchenne muscular dystrophy (DMD), according to a study published online on January 2 in the Journal of Cell Biology (www.jcb.org). As DMD patients age, their damaged muscle cells are gradually replaced by collagen-rich, fibrous tissue. This muscle fibrosis is partly induced by the growth factor TGF-beta, which is highly activated in DMD patients, though exactly how...

2011-12-19 11:22:00

TUCSON, Ariz., Dec. 19, 2011 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association (MDA) has awarded $750,000 to Summit PLC, a UK biotechnology company, to continue development of an experimental drug that may become a viable treatment for boys with Duchenne muscular dystrophy (DMD). The funding comes from MDA Venture Philanthropy (MVP), a part of MDA's translational research program. DMD is one of nine types of muscular dystrophy, a group of genetic, degenerative diseases primarily...

2011-12-19 07:00:00

CARLSBAD, Calif., Dec. 19, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Isis is developing ISIS-SMNRx as a potential treatment for all Types of SMA. "SMA is a devastating disease that leads to the loss of motor neurons resulting in muscle weakness...

2011-12-01 10:52:46

Researchers at the University of North Carolina at Chapel Hill have shown that it is safe to cut and paste together different viruses in an effort to create the ultimate vehicle for gene therapy. In a phase I clinical trial, the investigators found no side effects from using a "chimeric" virus to deliver replacement genes for an essential muscle protein in patients with muscular dystrophy. "This trial demonstrates that gene therapy is no longer limited by the viruses we find in nature, and...